CO2017011482A2 - Inhibidores de bromodominio - Google Patents

Inhibidores de bromodominio

Info

Publication number
CO2017011482A2
CO2017011482A2 CONC2017/0011482A CO2017011482A CO2017011482A2 CO 2017011482 A2 CO2017011482 A2 CO 2017011482A2 CO 2017011482 A CO2017011482 A CO 2017011482A CO 2017011482 A2 CO2017011482 A2 CO 2017011482A2
Authority
CO
Colombia
Prior art keywords
methylisoquinolin
methylsulfonylphenyl
cyclopropylmethoxy
pharmaceutical compositions
bromodomain
Prior art date
Application number
CONC2017/0011482A
Other languages
English (en)
Inventor
Jeffrey Alan Stafford
James Marvin Veal
Juan Manuel Betancort
Ryan Stansfield
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of CO2017011482A2 publication Critical patent/CO2017011482A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe aquí el inhibidor de bromodominio 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona, que incluye formas cristalinas, formas amorfas, solvatos e hidratos de los mismos, así como composiciones farmacéuticas que incluyen este inhibidor de bromodominio. En algunas realizaciones, la composición farmacéutica comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona que se ha procesado por micronización o dispersión secada por pulverización. En algunas realizaciones, la composición farmacéutica comprende además al menos un polímero. En algunas realizaciones, las composiciones farmacéuticas comprenden una matriz polimérica sólida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona son útiles para el tratamiento del cáncer o enfermedad neoplásica.
CONC2017/0011482A 2015-04-22 2017-11-08 Inhibidores de bromodominio CO2017011482A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22
PCT/US2016/029029 WO2016172618A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Publications (1)

Publication Number Publication Date
CO2017011482A2 true CO2017011482A2 (es) 2018-01-31

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011482A CO2017011482A2 (es) 2015-04-22 2017-11-08 Inhibidores de bromodominio

Country Status (22)

Country Link
US (1) US20160310423A1 (es)
EP (1) EP3285770A4 (es)
JP (1) JP2018513863A (es)
KR (1) KR20170139119A (es)
CN (1) CN107613981A (es)
AR (1) AR104340A1 (es)
AU (1) AU2016252992A1 (es)
BR (1) BR112017022691A2 (es)
CA (1) CA2983446C (es)
CL (1) CL2017002679A1 (es)
CO (1) CO2017011482A2 (es)
EA (1) EA201792317A1 (es)
EC (1) ECSP17071545A (es)
HK (1) HK1243948A1 (es)
IL (1) IL255120B (es)
MX (2) MX2017013501A (es)
PE (1) PE20180036A1 (es)
PH (1) PH12017501933A1 (es)
SG (1) SG11201708627TA (es)
TW (1) TW201642860A (es)
WO (1) WO2016172618A1 (es)
ZA (1) ZA201707186B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2017345468B2 (en) * 2016-10-20 2022-06-02 Celgene Quanticel Research, Inc. Bromodomain inhibitor
KR102587839B1 (ko) * 2016-10-27 2023-10-11 셀젠 콴티셀 리서치, 인크. 브로모도메인 및 엑스트라-말단 단백질 억제제 병용 치료요법
MX2021000657A (es) * 2018-07-23 2021-05-12 Celgene Quanticel Res Inc Proceso para la preparacion de inhibidor de bromodominio.
JP2024507232A (ja) * 2021-02-22 2024-02-16 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 前立腺がんの治療に用いるブロモドメイン（ｂｅｔ）阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
FI3640241T3 (fi) * 2013-10-18 2023-01-13 Bromodomeeni-inhibiittorit
AU2017345468B2 (en) * 2016-10-20 2022-06-02 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Also Published As

Publication number Publication date
IL255120B (en) 2021-03-25
MX2017013501A (es) 2018-02-09
PH12017501933A1 (en) 2018-03-19
US20160310423A1 (en) 2016-10-27
PE20180036A1 (es) 2018-01-09
KR20170139119A (ko) 2017-12-18
EA201792317A1 (ru) 2018-03-30
MX2020010899A (es) 2022-02-15
ZA201707186B (en) 2019-01-30
SG11201708627TA (en) 2017-11-29
BR112017022691A2 (pt) 2018-07-17
WO2016172618A1 (en) 2016-10-27
TW201642860A (zh) 2016-12-16
AU2016252992A1 (en) 2017-11-09
AR104340A1 (es) 2017-07-12
IL255120A0 (en) 2017-12-31
CA2983446A1 (en) 2016-10-27
EP3285770A1 (en) 2018-02-28
CN107613981A (zh) 2018-01-19
ECSP17071545A (es) 2017-12-01
CA2983446C (en) 2024-04-09
EP3285770A4 (en) 2018-10-31
NZ736630A (en) 2024-03-22
JP2018513863A (ja) 2018-05-31
CL2017002679A1 (es) 2018-05-25
HK1243948A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
CO2017011482A2 (es) Inhibidores de bromodominio
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
UY37098A (es) Moduladores de ror-gamma
CL2018001230A1 (es) Tratamiento de osteoartritis
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2019001339A1 (es) Inhibidores de la magl.
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2019001335A1 (es) Inhibidores de magl.
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
AR109859A1 (es) Inhibidor de bromodominio
CL2017002229A1 (es) Inhibidores de bace1.
CU20190002A7 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet